Pharmaceutical composition as well as preparation method and application thereof

By using thin-film dispersion method to incorporate the β-cyclodextrin inclusion of Res and Cur as oil phase, the problem of the competitive space between curcumin and liposomes is solved and the loading of resveratrol is improved The drug dosage and the stability of the double-loaded drug liposomes significantly enhanced the inhibitory effect on tumor cells and prolonged the survival time of mice.

CN118976122APending Publication Date: 2024-11-19TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411066235.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

In the existing preparation methods for co-carrying liposomes of curcumin and resveratrol, the affinity of curcumin and liposomes is stronger, resulting in a decrease in the drug loading of resveratrol, affecting its stability and release behavior, and reducing it. The mass of double drug-loaded liposomes.

Method used

By using the thin-film dispersion method, the β-cyclodextrin inclusion compound containing Res was loaded into the liposome as an aqueous phase packet, and then Cur was loaded into the lipid bilayer as an oil phase packet to prepare a double-load drug. Liposomes increase the drug loading of Res and maintain the stability of Cur packing.

Benefits of technology

The prepared curcumin and resveratrol double-loaded liposomes are stable, with excellent drug-loading characteristics, which can significantly increase the drug-loading volume of Res without affecting Cur's loading. In vitro and animal experiments show that it is stronger for tumor cells. The inhibitory effect of the mice prolongs the survival time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976122A_ABST
    Figure CN118976122A_ABST
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition, a preparation method thereof and application of the pharmaceutical composition as an STING agonist, and belongs to the technical field of antitumor drugs. The preparation method comprises the following steps: preparing a resveratrol solution and a beta-cyclodextrin solution; dropwise adding the resveratrol solution into the beta-cyclodextrin solution, sequentially heating, stirring, cooling, standing and filtering to obtain filtrate, and freeze-drying the filtrate to obtain a resveratrol / beta-cyclodextrin inclusion compound; soybean lecithin, cholesterol and curcumin are dissolved in a mixed solvent and subjected to rotary evaporation, and curcumin lipidosome is obtained; the preparation method comprises the following steps: dissolving a resveratrol / beta-cyclodextrin inclusion compound in distilled water, adding into a container containing a curcumin liposome membrane, sequentially carrying out heating stirring, ultrasonic treatment and centrifugation to remove unencapsulated free drugs and supernatant in a precipitate so as to obtain the pharmaceutical composition, so that the drug loading capacity of Res is improved on the premise of not influencing Cur encapsulation, the bioavailability of the curcumin is improved, and the bioavailability of the curcumin is improved. The compound has better effects of inhibiting activity, proliferation and tumor balling of tumor cells and resisting metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of anti-tumor drugs, and specifically relates to a drug composition and a preparation method and application thereof. Background Art

[0002] Curcumin is a hydrophobic polyphenol compound extracted from the rhizome of turmeric, with a molecular formula of C 21 H 20 O6 has a wide range of pharmacological activities such as anti-inflammatory, antiviral, and antibacterial. In addition, it also has a broad-spectrum anti-tumor effect and can be used to treat various types of malignant tumors such as breast cancer, gastric cancer, liver cancer, and colorectal cancer. Studies have shown that Cur eliminates tumors by inhibiting the growth and spread of tumor cells, and can also enhance the body's sensitivity to tumor cells. However, due to factors such as poor water solubility, low absorption efficiency, rapid metabolism, and rapid systemic elimination of Cur, its bioavailability is low. Therefore, the various Cur drug delivery systems currently developed are largely aimed at increasing its solubility and bioavailability, and expanding the development and application of Cur.

[0003] Res (resveratrol) is a natural polyphenol compound found in many plants such as mulberry, peanuts and grapes. It has great application prospects in anti-inflammatory, anti-cancer, and protecting body functions. Studies have shown that Res has a good inhibitory effect on non-breast cancer, small cell lung cancer, colon cancer, etc. However, due to its poor water solubility and rapid metabolism, its bioavailability is low. Therefore, many researchers use Res in combination with other drugs to improve its bioavailability.

[0004] Nano drug delivery systems mainly use nanocarriers to load therapeutic drug molecules, which can improve the solubility of poorly soluble drugs, increase drug concentrations in tumor sites, reduce the distribution of drugs in healthy tissues, and reduce the toxic side effects of drugs on normal tissues. Nowadays, liposome delivery systems have become a research hotspot in the field of nanobiomedical materials, and have received keen attention from academia and industry. Liposomes are bilayer closed vesicles composed of phospholipids and cholesterol. As drug carriers, they have good biocompatibility and biodegradability, extend half-life, and reduce drug toxicity, so they are widely used. Researchers have used nanoprecipitation to prepare high-molecular NPs loaded with Cur+Res, and used Res, Cur, DSPE-PEG2000 or DSPE-PEG2000-sp94, DSPC and cholesterol to prepare NPs in proportion. After hydration, they were ultrasonically treated and extruded through a 200nm polycarbonate membrane to prepare curcumin and resveratrol co-loaded nanoparticles for synergistic treatment of hepatocellular carcinoma.

[0005] The existing method for preparing curcumin and resveratrol co-loaded liposomes is usually to directly encapsulate curcumin and resveratrol into lipid materials. Curcumin and resveratrol will compete for the limited liposome space. Since curcumin has a stronger affinity with liposomes, the drug loading amount of resveratrol in the liposomes may decrease, and affect its stability and release behavior, thereby affecting the quality of the dual-drug loaded liposomes. Summary of the invention

[0006] In view of this, the object of the present invention is to provide a pharmaceutical composition and a preparation method and application thereof. The preparation method first uses a thin film dispersion method to load a β-cyclodextrin inclusion complex encapsulating Res into a liposome as an aqueous phase, and then loads Cur into a lipid bilayer as an oil phase to prepare a dual-drug-loaded liposome. The prepared curcumin and resveratrol dual-drug-loaded liposome solution dispersion system is stable and not prone to aggregation, has good drug loading properties, has more advantages in encapsulating Res, and increases the drug loading amount of Res without affecting Cur encapsulation.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a method for preparing a pharmaceutical composition, comprising the following steps:

[0009] 1) preparing a resveratrol solution and a β-cyclodextrin solution;

[0010] 2) dropping the resveratrol solution into the β-cyclodextrin solution, heating and stirring, cooling, standing, filtering to obtain a filtrate, and freeze-drying the filtrate to obtain a resveratrol / β-cyclodextrin inclusion complex;

[0011] 3) dissolving soybean lecithin, cholesterol and curcumin in a mixed solvent and performing rotary evaporation to obtain curcumin liposomes;

[0012] 4) dissolving the resveratrol / β-cyclodextrin inclusion complex in distilled water, adding the mixture to a container containing the curcumin liposome membrane, and sequentially heating, stirring, ultrasonicating, and centrifuging to remove the unencapsulated free drug in the precipitate, and obtaining the pharmaceutical composition as the supernatant;

[0013] In the step 1), the β-cyclodextrin is carboxymethyl-β-cyclodextrin or hydroxypropyl-β-cyclodextrin.

[0014] CD is a cyclic oligosaccharide compound obtained by enzymatic hydrolysis and cyclization of starch, with a hydrophobic cavity and a hydrophilic shell. Poorly soluble drugs can be encapsulated in the cavity structure to form inclusion complexes to improve the solubility and bioavailability of poorly soluble drugs. CM-β-CD (carboxymethyl-β-cyclodextrin) and HP-β-CD (hydroxypropyl-β-cyclodextrin) are etherified derivatives obtained by chemical modification of β-CD. They have low surface activity, thermal stability and good water solubility. They are one of the most widely used solubilizers, injections and excipients. They can form inclusion complexes with poorly water-soluble drugs, control the release of drugs, reduce the toxic and side effects of drugs, improve their solubility and stability, and improve the bioavailability of poorly soluble drugs.

[0015] Preferably, the solvent of the resveratrol solution in step 1) is methanol; the ratio of resveratrol to solvent is 0.1 mol: 4-7 mL.

[0016] Preferably, the solvent of the β-cyclodextrin solution in step 1) is distilled water; the ratio of β-cyclodextrin to solvent is 0.1 mol: 40-60 mL.

[0017] Preferably, in step 2), the ratio of resveratrol to β-cyclodextrin is 1:1 mol.

[0018] Preferably, the heating and stirring temperature in step 2) is 40-50°C, more preferably 45°C, and the stirring time is 6-10 hours, more preferably 8 hours.

[0019] Preferably, the cooling in step 2) is gradient cooling, and the specific parameters of the gradient cooling are: starting from 45° C., reducing by 0.2° C. per minute until reaching room temperature.

[0020] The present invention can further remove methanol by adopting a gradient cooling method.

[0021] Preferably, the filtration in step 2) uses a 0.45 μm microporous filter membrane.

[0022] Preferably, in step 3), the ratio of soybean lecithin, cholesterol, curcumin and mixed solvent is 0.1-0.2g:0.02:0.03g:0.003-0.004g:5-7mL, and more preferably 0.1104g:0.0280g:0.0036g:6mL.

[0023] Preferably, the mixed solvent is a mixture of dichloromethane and anhydrous methanol in a ratio of 2 mL:1 mL.

[0024] Preferably, the temperature of the rotary evaporation in step 3) is 45°C.

[0025] Preferably, the amount of the resveratrol / β-cyclodextrin inclusion complex and curcumin liposome used in step 4) is: the resveratrol and curcumin contained therein are weighed according to a molar ratio of 1:1.

[0026] Preferably, in step 4), the ratio of the total mass of the resveratrol / β-cyclodextrin inclusion complex and curcumin liposome to distilled water is 0.15-0.2 g, more preferably 0.163 g:15 mL.

[0027] Preferably, the heating and stirring in step 4) is carried out at a temperature of 40° C. and for a time of 2 h.

[0028] Preferably, in step 4), the ultrasonic power is 100 W and the ultrasonic time is 5 min.

[0029] Preferably, the centrifugal temperature in step 4) is 4°C and the centrifugal speed is 15000 r / min.

[0030] In a second aspect, the present invention provides a pharmaceutical composition prepared by the above preparation method.

[0031] In a third aspect, the present invention provides use of the above-mentioned pharmaceutical composition as a STING agonist.

[0032] Contains at least the following beneficial technical effects:

[0033] 1) The present invention prepares dual-drug-loaded liposomes by using a thin film dispersion method to load a β-cyclodextrin inclusion complex loaded with Res as an aqueous phase into the liposome, and then loads Cur as an oil phase into the lipid bilayer, thereby overcoming the problem of curcumin and resveratrol competing for limited liposome space, and improving the drug loading of Res without affecting the loading of Cur.

[0034] 2) The curcumin and resveratrol dual-drug-loaded liposome solution dispersion system prepared by the present invention is stable and not prone to aggregation.

[0035] 3) The present invention uses in vitro cell and animal experiments, and the results show that the dual-drug liposomes can act on the STING pathway. Compared with single drugs, the dual-drug liposomes have better inhibitory effects on tumor cell activity, proliferation, tumor spheroidization and anti-metastasis, and can significantly prolong the survival time of postoperative mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The product properties of blank liposomes, HP-Res / Cur, and CM-Res / Cur.

[0037] Figure 2 The particle size and PDI results of HP-Res / Cur and CM-Res / Cu are shown.

[0038] Figure 3 Transmission electron microscope (TEM) images of HP-Res / Cur and Cur-Lip.

[0039] Figure 4 Ultraviolet (UV) spectra of Cur and Res monomers, blank liposomes, HP-Res / Cur, and CM-Res / Cu.

[0040] Figure 5 These are the differential thermal analysis (DTA) diagrams of Cur, Res monomers, blank liposomes, HP-Res / Cur, and CM-Res / Cu.

[0041] Figure 6 Infrared spectra (IR) of Cur and Res monomers, blank liposomes, HP-Res / Cur, and CM-Res / Cu.

[0042] Figure 7 EE% and DL% diagrams of HP-Res / Cur and CM-Res / Cu.

[0043] Figure 8 In vitro release diagram of HP-Res / Cur and CM-Res / Cu.

[0044] Fig. 9 This is a cell proliferation curve under the action of HP-Res / Cur.

[0045] Fig.10 This is a diagram of the spheroidization experiment of 4T1 tumor cells using HP-Res / Cur.

[0046] Fig.11 This is a diagram showing the clone formation of 4T1 tumor cells under the action of HP-Res / Cur.

[0047] Fig.12 Part of the protein immunoblotting images of HP-Res / Cur acting on 4T1 tumor cells.

[0048] Fig.13 This is the real-time fluorescence quantitative PCR graph of HP-Res / Cur acting on 4T1 tumor cells.

[0049] Fig.14 This is an imaging image of tumor metastasis in mice implanted with 4T1 tumor cells and then excised after the tumor was formed by HP-Res / Cur.

[0050] Fig.15 This is the survival curve of mice after HP-Res / Cur administration. DETAILED DESCRIPTION

[0051] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.

[0052] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.

[0053] It is obvious to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the main idea or essential features of the present invention. Therefore, from all points of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention, and any reference numerals in the claims should not be regarded as limiting the claims involved.

[0054] In addition, it should be understood that although this specification is described according to the implementation modes, not every implementation mode includes only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation modes that can be understood by those skilled in the art. These other implementation modes are also covered within the protection scope of the present invention.

[0055] It should also be understood that the specific embodiments described above are only used to explain the present invention, and the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field, within the technical scope disclosed by the present invention, can make equivalent replacements or changes based on the technical solutions and inventive concepts of the present invention, which should be covered by the protection scope of the present invention / invention.

[0056] Source of raw materials: Carboxymethyl-β-cyclodextrin (CM-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) were purchased from Wacker Company, Germany, with a purity of 99%.

[0057] Example 1

[0058] 1) Preparation of resveratrol solution: 0.1 mol of resveratrol was weighed and dissolved in 5 mL of methanol and ultrasonicated until completely dissolved.

[0059] Preparation of carboxymethyl-β-cyclodextrin solution: weigh 0.1 mol of carboxymethyl-β-cyclodextrin and dissolve it in 50 mL of distilled water.

[0060] 2) The resveratrol solution was uniformly dripped into the carboxymethyl-β-cyclodextrin aqueous solution and stirred at 45°C for 8 hours, then cooled at a cooling rate of 0.2°C / min to volatilize the methanol, allowed to stand for 1 hour, and then filtered with a 0.45 μm microporous filter membrane to obtain a filtrate, which was spread flat in a culture dish, pre-frozen at -80°C for 24 hours until the solution was completely frozen into a solid, and then freeze-dried for 10 hours to obtain a white fluffy flocculent, thereby obtaining a resveratrol / carboxymethyl-β-cyclodextrin inclusion complex;

[0061] 3) Soybean lecithin, cholesterol and curcumin were weighed according to 0.1104g: 0.0280g: 0.0036g and dissolved in 6mL of mixed solvent, ultrasonicated until completely dissolved, and the solution was transferred to an eggplant-shaped bottle, and rotary evaporated in a 45°C water bath to form a dense and complete yellow film. After the film was formed, the eggplant-shaped bottle was removed to obtain curcumin liposomes; the mixed solvent was a mixture of dichloromethane and anhydrous methanol in a ratio of 2mL:1mL;

[0062] 4) Resveratrol / carboxymethyl-β-cyclodextrin inclusion complex and curcumin liposome were weighed according to a molar ratio of resveratrol to curcumin of 1:1, the resveratrol / carboxymethyl-β-cyclodextrin inclusion complex was dissolved in 15 mL of distilled water, added to the eggplant-shaped bottle of curcumin liposomes that had already formed a film, placed on a magnetic stirrer, heated and stirred for hydration for 2 h to fully dissolve the film, collected the hydrated solution, and used an ultrasonic cell disruptor to ultrasonicate for 5 min at a power of 100 W to further disperse the liposome solution, and the sonicated solution was centrifuged at 4 ° C and 15000 r / min for 15 min to remove the unencapsulated free drug in the precipitate, and the supernatant was obtained.

[0063] Example 2

[0064] 1) Preparation of resveratrol solution: 0.1 mol of resveratrol was weighed and dissolved in 4 mL of methanol and ultrasonicated until completely dissolved.

[0065] Preparation of carboxymethyl-β-cyclodextrin solution: weigh 0.1 mol of carboxymethyl-β-cyclodextrin and dissolve it in 40 mL of distilled water.

[0066] 2) The resveratrol solution was uniformly dripped into the carboxymethyl-β-cyclodextrin aqueous solution and stirred at 40°C for 6 hours, then cooled at a cooling rate of 0.2°C / min to volatilize the methanol, allowed to stand for 1 hour, and then filtered with a 0.45 μm microporous filter membrane to obtain a filtrate, which was spread in a culture dish, pre-frozen at -80°C for 24 hours until the solution was completely frozen into a solid, and then freeze-dried for 10 hours to obtain a white fluffy flocculent, thereby obtaining a resveratrol / carboxymethyl-β-cyclodextrin inclusion complex;

[0067] 3) Soybean lecithin, cholesterol and curcumin were weighed according to 0.1g:0.02g:0.003g and dissolved in 5mL of mixed solvent, ultrasonicated until completely dissolved, and the solution was transferred to an eggplant-shaped bottle, and rotary evaporated in a 45°C water bath to form a dense and complete yellow film. After the film was formed, the eggplant-shaped bottle was removed to obtain curcumin liposomes; the mixed solvent was a mixture of dichloromethane and anhydrous methanol in a ratio of 2mL:1mL;

[0068] 4) Resveratrol / carboxymethyl-β-cyclodextrin inclusion complex and curcumin liposome were weighed according to a molar ratio of resveratrol to curcumin of 1:1, the resveratrol / carboxymethyl-β-cyclodextrin inclusion complex was dissolved in 15 mL of distilled water, added to the eggplant-shaped bottle of curcumin liposomes that had already formed a film, placed on a magnetic stirrer, heated and stirred for hydration for 2 h to fully dissolve the film, collected the hydrated solution, and used an ultrasonic cell disruptor to ultrasonicate for 5 min at a power of 100 W to further disperse the liposome solution, and the sonicated solution was centrifuged at 4 ° C and 15000 r / min for 15 min to remove the unencapsulated free drug in the precipitate, and the supernatant was obtained.

[0069] Example 3

[0070] 1) Preparation of resveratrol solution: 0.1 mol of resveratrol was weighed and dissolved in 7 mL of methanol by ultrasonication until completely dissolved.

[0071] Preparation of carboxymethyl-β-cyclodextrin solution: weigh 0.1 mol of carboxymethyl-β-cyclodextrin and dissolve it in 60 mL of distilled water.

[0072] 2) The resveratrol solution was uniformly dripped into the β-CD aqueous solution and stirred at 50°C for 10 hours, then cooled at a cooling rate of 0.2°C / min to volatilize the methanol, allowed to stand for 1 hour, and then filtered with a 0.45 μm microporous filter membrane to obtain a filtrate, which was spread flat in a culture dish, pre-frozen at -80°C for 24 hours until the solution was completely frozen into a solid, and then freeze-dried for 10 hours to obtain a white fluffy flocculent, thereby obtaining a resveratrol / -cyclodextrin inclusion complex;

[0073] 3) Soybean lecithin, cholesterol and curcumin were weighed according to 0.2g:0.03g:0.004g and dissolved in 7mL of mixed solvent, ultrasonicated until completely dissolved, and the solution was transferred to an eggplant-shaped bottle, and rotary evaporated in a 45°C water bath to form a dense and complete yellow film. After the film was formed, the eggplant-shaped bottle was removed to obtain curcumin liposomes; the mixed solvent was a mixture of dichloromethane and anhydrous methanol in a ratio of 2mL:1mL;

[0074] 4) Resveratrol / β-cyclodextrin inclusion complex and curcumin liposome were weighed according to a molar ratio of resveratrol to curcumin of 1:1, the resveratrol / β-cyclodextrin inclusion complex was dissolved in 15 mL of distilled water, added to the eggplant-shaped bottle of curcumin liposomes that had already formed a film, placed on a magnetic stirrer, heated and stirred for hydration for 2 h to fully dissolve the film, collected the hydrated solution, and used an ultrasonic cell disruptor to ultrasonicate for 5 min at a power of 100 W to further disperse the liposome solution, and the sonicated solution was centrifuged at 4 ° C and 15000 r / min for 15 min to remove the unencapsulated free drug in the precipitate, and the supernatant was obtained.

[0075] Example 4

[0076] The preparation method of this embodiment is the same as that of embodiment 1, except that hydroxypropyl-β-cyclodextrin (HP-β-CD) is used in preparing the β-cyclodextrin solution in step 1).

[0077] The following experimental examples were tested with the dual drug-loaded liposomes obtained in Example 1 and Example 4. The prepared curcumin and resveratrol dual drug-loaded liposomes were recorded as CM-Res / Cur and HP-Res / Cur according to the type of β-cyclodextrin used in the preparation process, that is, Example 1 was CM-Res / Cur and Example 4 was HP-Res / Cur.

[0078] Experimental Example 1

[0079] Characterization of the physicochemical properties of curcumin and resveratrol dual-drug liposomes

[0080] 1. Appearance: Observe the appearance of blank liposomes and dual-drug loaded liposomes, see Figure 1 , from left to right: blank liposomes, HP-Res / Cur dual-drug loaded liposomes and CM-Res / Cur dual-drug loaded liposomes.

[0081] The dual-drug-loaded liposomes were light yellow, clear and transparent liquids, and the dual-drug-loaded liposomes of HP-Res / Cur were clearer than those of CM-Res / Cur.

[0082] 2. Particle size and PDI determination: The particle size and PDI of HP-Res / Cur and CM-Res / Cur dual-drug liposomes stored at 4°C for 15 days were determined using a particle size analyzer. Figure 2 .

[0083] The particle sizes of the two liposomes were both less than 150 nm, and the PDIs were both less than 0.2, which indicated that the two dual drug delivery systems were relatively stable and would not aggregate when stored at 4°C for 15 days.

[0084] 3. Transmission electron microscopy (TEM) and potential measurement: Observe the particle size distribution and appearance of dual-drug loaded liposomes under the microscope and measure the membrane potential. Figure 3 .

[0085] The particle size of the dual-drug liposomes is about 100nm, and the appearance is a complete sphere. The particles are evenly distributed and there is no agglomeration. The membrane potential is -25.03±0.57mV, and the absolute value is greater than 20mV, indicating that the liposome solution dispersion system is stable and not prone to aggregation.

[0086] Experimental Example 2

[0087] Physical state characterization of curcumin and resveratrol dual-drug liposomes

[0088] 1. Characterization by ultraviolet spectroscopy (UV): The Cur and Res monomers, blank liposomes, and the two dual-drug-loaded liposomes prepared in Example 1 and Example 4 were subjected to full-wavelength ultraviolet scanning, with methanol as the reference solution and the scanning range set to 200-600 nm. Figure 4 .

[0089] The two curves of CM-Res / Cur dual-drug loaded liposomes and HP-Res / Cur dual-drug loaded liposomes both showed the characteristic absorption peak of Res at 306nm and the characteristic absorption peak of Cur at 425nm, which proved that the two drugs were successfully loaded into the liposomes.

[0090] 2. Characterization by differential thermal analysis (DTA): Put the two monomers Cur and Res, blank liposomes, the two dual-drug liposomes prepared in Example 1 and Example 4, and the reference material into small crucibles respectively, and place them in a heating furnace to heat up. If the sample has no thermal effect during the heating process, the temperature difference between the sample temperature and the reference material temperature is zero; if the sample has a thermal effect at a certain temperature, a temperature difference will occur, and the relationship between the temperature difference and the temperature is recorded to obtain the DTA curve, see Figure 5 .

[0091] Cur, a sharp endothermic peak was observed at 181℃; b is Res, an obvious endothermic peak was observed at 267℃; c is blank liposome, which can be seen as a gentle straight line, and no endothermic peak or exothermic peak was observed; d is a solid mixture of blank liposome and Cur, with an endothermic peak at 176℃, close to the endothermic peak of Cur; e is a solid mixture of blank liposome and Res, an endothermic peak was observed at 253℃, close to the endothermic peak of Res, indicating that neither drug interacted with soybean lecithin, but was physically mixed, so no new endothermic peak appeared. f is CM-Res / Cur dual-drug liposome, no characteristic peaks of Cur or Res were observed, and a new endothermic peak appeared at 216℃, indicating that the drug interacted with soybean lecithin, changing the original thermal process and generating a new peak, indicating that CM-Res / Cur dual-drug liposome was generated. g is HP-Res / Cur dual-drug loaded liposomes, and a not particularly obvious and relatively broad endothermic peak appeared at the 138°C position. The characteristic peaks of the two drugs were still not observed in this curve. As described above, HP-Res / Cur dual-drug loaded liposomes were generated.

[0092] 3. Characterization by infrared spectroscopy (IR): The characteristic absorption peaks of Cur and Res monomers, blank liposomes, and the two dual-drug-loaded liposomes prepared in Example 1 and Example 4 were observed by infrared spectrometer to determine whether Res and Cur were successfully loaded into the liposomes and whether they had an effect on the structure of the film-forming material in the liposomes. Figure 6 .

[0093] Res at 3292cm -1 , 1590cm -1 、1153cm -1 and 832cm -1 There is a characteristic absorption peak at 3500cm -1 , 1508cm -1 、1281cm -1 and 961cm -1 The physical mixture of Res and Cur with a molar ratio of 1:1 has a characteristic absorption peak at 3502 cm -1 、3298cm -1 、1592cm -1 、1506cm -1 、1276cm -1 、1153cm -1 、963cm -1 、829cm -1Absorption peaks were observed at all sites. By comparison, it contains all the characteristic peaks of Res and Cur, which is the superposition of the unique absorption peaks of the two. This shows that there is no chemical interaction between the two, but only a simple physical mixing. 2- The stretching vibration is located at 1088 cm -1 The CH2 symmetric stretching vibration of the fatty acid hydrocarbon chain in the hydrophobic part is located at 2926 cm -1 The asymmetric stretching vibration is located at 2855 cm -1 The infrared curves of blank liposomes, Cur-loaded liposomes, CM-Res / Cur dual-drug-loaded liposomes, and HP-Res / Cur dual-drug-loaded liposomes all showed a peak at 2926 cm -1 、2855cm -1 、1088cm -1 Compared with the peak of soybean lecithin, no new peaks and chemical shifts appeared, and the characteristic absorption peaks of Res and Cur were shielded, which proved that Res and Cur were successfully encapsulated into the interior of the liposomes and had no effect on the structure of the membrane-forming material in the liposomes.

[0094] Experimental Example 3

[0095] Quality evaluation of curcumin and resveratrol dual-drug liposomes

[0096] 1.EE% and DL%: Calculate the EE% and DL% of Cur and Res in HP-Res / Cur and CM-Res / Cur dual-drug liposomes at 4°C for 15 days. Figure 7 .

[0097] Both dual-drug loaded liposomes have good drug loading properties and can stably encapsulate drugs. In addition, HP-Res / Cur liposomes have more advantages in encapsulating Res, and can increase the drug loading capacity of Res without affecting the encapsulation of Cur.

[0098] 2. In vitro release: The in vitro release of the two dual-drug liposomes containing Cur / Res drugs within 24 hours was observed at pH 7.4 or 6.5. Figure 8 .

[0099] In an environment of pH 6.5, the in vitro release effects of the two drugs Cur / Res in the two dual-drug-loaded liposomes were better than those in the release medium of pH 7.4, and in the alkaline release medium of pH 7.4, some in vitro release curves first rose and then fell, which may be related to the instability of Cur in neutral and alkaline solutions and the effect of the release medium of pH 7.4 on the membrane structure of the liposomes. In addition, in the release medium of pH 6.5, the in vitro release effect of Res in HP-Res / Cur dual-drug-loaded lipids was better than that of CM-Res / Cur dual-drug-loaded liposomes, and there was no negative impact on the in vitro release of Cur, maintaining a stable release.

[0100] Experimental Example 4

[0101] Antitumor evaluation of curcumin and resveratrol dual-drug liposomes

[0102] 1. Cell proliferation experiment: observe the inhibitory effect of HP-Res / Cur on 4T1 cells, see Fig. 9 .

[0103] Compared with single drug and single drug liposomes, dual drug-loaded liposomes have better activity in inhibiting tumor cell proliferation.

[0104] 2. Tumor sphere formation experiment: observe the inhibitory effects of HP-Res / Cur, single drug and single drug liposome on 4T1 cells, see Fig.10 .

[0105] Dual-drug loaded liposomes have the ability to inhibit tumor spheroidization, anti-metastasis, and inhibit proliferation.

[0106] 3. Clone formation experiment: observe the inhibitory effect of HP-Res / Cur with single drug and single drug liposome on 4T1 cells, see Fig.11 .

[0107] The dual-drug loaded liposomes have a significant inhibitory effect on proliferation.

[0108] 4. Western blotting experiment: observe the expression of some anti-apoptotic and pro-metastasis proteins of 4T1 cells by HP-Res / Cur and single drug and single drug liposome, see Fig.12 .

[0109] Dual-drug loaded liposomes can inhibit the expression of some anti-apoptotic and pro-metastasis proteins, affect the stemness of tumor cells, and have more obvious effects than single drugs.

[0110] 5. Real-time fluorescence quantitative PCR experiment: observe the effects of HP-Res / Cur, single drug and single drug liposome on CCL-4, CXCL-10, IFN-α, IFN-β and other immune response factors of 4T1 cells, and prove the action pathway of dual drug-loaded liposomes, see Fig.13 .

[0111] CCL-4, CXCL-10, IFN-α, and IFN-β are all type I immune response factors, proving that dual-drug liposomes can act on the STING pathway.

[0112] 6. Small animal imaging experiment: The survival rate and bioluminescent signal intensity of the in vivo images of 4T1 cell tumor-bearing mice after administration of HP-Res / Cur prepared in Example 1 and single drug and single drug liposome were observed using a small animal imaging system, and the survival time of the mice after tumor removal surgery was recorded. Figure 14-15 .

[0113] The survival rate of the HP-Cur / Res dual-drug liposome administration group was significantly increased, proving that the dual-drug liposome can prolong the survival time of postoperative mice.

[0114] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A method for preparing a pharmaceutical composition, characterized in that: The following steps are involved: 1) preparing a resveratrol solution and a β-cyclodextrin solution; 2) dropping the resveratrol solution into the β-cyclodextrin solution, heating and stirring, cooling, standing, filtering to obtain a filtrate, and freeze-drying the filtrate to obtain a resveratrol / β-cyclodextrin inclusion complex; 3) dissolving soybean lecithin, cholesterol and curcumin in a mixed solvent and performing rotary evaporation to obtain curcumin liposomes; 4) dissolving the resveratrol / β-cyclodextrin inclusion complex in distilled water, adding the mixture to a container containing the curcumin liposome membrane, and sequentially heating, stirring, ultrasonicating, and centrifuging to remove the unencapsulated free drug in the precipitate, and obtaining the pharmaceutical composition as the supernatant; In the step 1), the β-cyclodextrin is carboxymethyl-β-cyclodextrin or hydroxypropyl-β-cyclodextrin.

2. The preparation method according to claim 1, characterized in that: In the step 2), the ratio of resveratrol to β-cyclodextrin is 1:1 mol.

3. The preparation method according to claim 1, characterized in that: The heating and stirring temperature in step 2) is 40-50° C., and the stirring time is 6-10 h.

4. The preparation method according to claim 1, characterized in that: The cooling in step 2) is a gradient cooling, and the specific parameters of the gradient cooling are: starting from 45° C., reducing by 0.2° C. per minute until reaching room temperature.

5. The preparation method according to claim 1, characterized in that: In the step 3), the ratio of soybean lecithin, cholesterol, curcumin and mixed solvent is 0.1-0.2 g: 0.02: 0.03 g: 0.003-0.004 g: 5-7 mL.

6. The preparation method according to claim 5, characterized in that: The mixed solvent is a mixture of dichloromethane and anhydrous methanol in a ratio of 2 mL:1 mL.

7. The preparation method according to claim 1, characterized in that: The amount of resveratrol / β-cyclodextrin inclusion complex and curcumin liposome used in step 4) is: resveratrol and curcumin contained therein are weighed according to a molar ratio of 1:

1.

8. The preparation method according to claim 1, characterized in that: In the step 4), the ratio of the total mass of the resveratrol / β-cyclodextrin inclusion complex and the curcumin liposome to distilled water is 0.15-0.2 g:15 mL.

9. A pharmaceutical composition, characterized in that Prepared according to the preparation method according to any one of claims 1 to 8.

10. Use of the pharmaceutical composition according to claim 9 as a STING agonist.